AR042968A1 - Anticuerpos de virus anti-dengue composiciones metodos y usos - Google Patents

Anticuerpos de virus anti-dengue composiciones metodos y usos

Info

Publication number
AR042968A1
AR042968A1 ARP040100270A ARP040100270A AR042968A1 AR 042968 A1 AR042968 A1 AR 042968A1 AR P040100270 A ARP040100270 A AR P040100270A AR P040100270 A ARP040100270 A AR P040100270A AR 042968 A1 AR042968 A1 AR 042968A1
Authority
AR
Argentina
Prior art keywords
dengue virus
methods
virus antibody
virus antibodies
antibody
Prior art date
Application number
ARP040100270A
Other languages
English (en)
Original Assignee
Novartis Ag
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Scripps Research Inst filed Critical Novartis Ag
Publication of AR042968A1 publication Critical patent/AR042968A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Por lo menos un anticuerpo del virus anti-dengue novedoso, ácidos nucleicos aislados que codifican por lo menos un anticuerpo del virus anti-dengue, vectores, células huésped, animales o plantas transgénicas, y métodos para hacer y utilizar los mismos, incluyendo composiciones terapéuticas, métodos y dispositivos. Reivindicación 1: Un anticuerpo del virus anti-dengue de mamífero aislado, que comprende por lo menos una región variable comprendiendo la secuencia de aminoácido establecida en SEC ID NOS: 3 o 4. Reivindicación 3: Un anticuerpo del virus anti-dengue de acuerdo con la reivindicación 1, en donde dicho anticuerpo une por lo menos una proteína NS del virus del dengue.
ARP040100270A 2003-01-31 2004-12-29 Anticuerpos de virus anti-dengue composiciones metodos y usos AR042968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44392403P 2003-01-31 2003-01-31

Publications (1)

Publication Number Publication Date
AR042968A1 true AR042968A1 (es) 2005-07-13

Family

ID=32825393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100270A AR042968A1 (es) 2003-01-31 2004-12-29 Anticuerpos de virus anti-dengue composiciones metodos y usos

Country Status (7)

Country Link
US (1) US7473424B2 (es)
EP (1) EP1592712A2 (es)
JP (1) JP2007524350A (es)
AR (1) AR042968A1 (es)
PE (1) PE20050197A1 (es)
TW (1) TW200508246A (es)
WO (1) WO2004067567A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894300A1 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus
JP4892548B2 (ja) * 2005-05-02 2012-03-07 アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル (アンセルム) Hivに対して中和活性を有する抗体又はその断片
BRPI0816916A2 (pt) * 2007-09-07 2014-09-30 Mevlabs Inc Formulações e dispositivos para liberação de compostos a artrópodes e microorganismos no interior dos mesmos.
WO2010043977A2 (en) * 2008-10-13 2010-04-22 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
AU2013202434B2 (en) * 2008-10-13 2016-01-28 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US20130189275A1 (en) * 2010-06-03 2013-07-25 University Of Rochester Compositions and methods for inhibition of or treatment of dengue virus infection
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
KR102356951B1 (ko) 2014-02-11 2022-01-27 비스테라, 인크. 뎅기열 바이러스에 대한 항체 분자 및 그의 용도
TWI511977B (zh) * 2014-02-27 2015-12-11 Univ Nat Cheng Kung 抗登革熱病毒非結構性蛋白1之單株抗體及其用途
WO2017011495A1 (en) * 2015-07-14 2017-01-19 Vanderbilt University Engineered antibodies against dengue virus
KR101763745B1 (ko) 2016-01-08 2017-08-01 전북대학교산학협력단 뎅기 바이러스 4가지 혈청형의 외막 도메인 ⅲ에 대한 단일클론 항체 및 이의 용도
TWI763660B (zh) 2016-03-25 2022-05-11 美商威特拉公司 登革病毒的抗體分子之配方設計
KR102269663B1 (ko) * 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR101995774B1 (ko) * 2018-05-08 2019-07-03 한국세라믹기술원 뎅기열 바이러스에 특이적으로 결합하는 피브로넥틴 edb 단백질 스캐폴드
US20210188948A1 (en) * 2018-08-07 2021-06-24 Chan Zuckerberg Biohub, Inc. Antibodies against dengue virus and related methods
CN115785262B (zh) * 2021-09-10 2023-09-22 东莞市朋志生物科技有限公司 一种抗登革ns1蛋白的抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501990A (en) * 1997-07-08 2002-09-27 Viventia Biotech Inc Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
AU754386B2 (en) * 1997-09-23 2002-11-14 Bavarian Nordic A/S Dengue virus antigens and treatment of dengue fever
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
FR2794864A1 (fr) * 1999-06-09 2000-12-15 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ, インコーポレイテッド 生物兵器防衛のための免疫療法

Also Published As

Publication number Publication date
US7473424B2 (en) 2009-01-06
US20040209244A1 (en) 2004-10-21
EP1592712A2 (en) 2005-11-09
TW200508246A (en) 2005-03-01
JP2007524350A (ja) 2007-08-30
WO2004067567A2 (en) 2004-08-12
WO2004067567A3 (en) 2004-11-25
PE20050197A1 (es) 2005-05-16

Similar Documents

Publication Publication Date Title
CY1119650T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos
AR038568A1 (es) Anticuerpos anti-a beta y su uso
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
NI200700155A (es) Anticuerpos anti-il-12, epitopes, composiciones, métodos y usos.
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
PE20061444A1 (es) Anticuerpo anti-mcp-1, composiciones, metodos y usos
BR0013542A (pt) Moléculas b7-4 e usos para as mesmas
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
RS52790B (en) MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT
EA200701362A1 (ru) Агонисты glp-1, композиции, способы и применения
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
ATE500323T1 (de) Subtilisin-variante
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
ATE398676T2 (de) Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
PE20061441A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
ATE473236T1 (de) Antigene von piscirickettsia salmonis und deren verwendung
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
DE60237613D1 (de) Neue pgc-1-isoformen und deren verwendungen
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
BR0316722A (pt) Constructos genéticos e composições compreendendo rre e cte e usos destes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal